567 / 1631
Pi3Ki: Duvelisib
•
Safety:
–
Neutropenia: 28%
–
Diarrhea: 15%
–
Grade 3 infection: 20%
–
CMV: 2.3%
•
Inhibitor of PI3K- delta and gamma isoforms.
•
Phase II study: Dynamo
–
Rituximab refractory
–
Refractory to alkylator or radioimmunotherapy
–
Primary endpoint: ORR
Flinn, I et al. ASH 2016